Ensysce Biosciences (ENSCW) Income from Continuing Operations (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Income from Continuing Operations of 3747464.0 for Q3 2025, down 684.92% year-over-year from 640683.0 in Q3 2024, and down 113.69% quarter-over-quarter from 1753675.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Income from Continuing Operations data on file, last reported at 3747464.0 in Q3 2025.
- Income from Continuing Operations for Q3 2025 came in at 3747464.0, down 684.92% year-over-year; the trailing twelve-month figure through Sep 2025 was 11050889.0 (down 39.29% YoY), and the FY2024 annual result was 8011731.0, up 27.64% from the prior year.
- Income from Continuing Operations eased to 3747464.0 in Q3 2025 per ENSCW's latest filing, from 1753675.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 640683.0 in Q3 2024 and troughed at 16911455.0 in Q3 2021.
- A 5-year average of 3831811.32 and a median of 2714963.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2024: Income from Continuing Operations slumped 2623.52% in 2021, then soared 123.6% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 2019232.0 in 2021, then sank by 207.24% to 6203831.0 in 2022, then soared by 43.58% to 3500484.0 in 2023, then declined by 2.23% to 3578382.0 in 2024, then slipped by 4.73% to 3747464.0 in 2025.
- Business Quant data shows ENSCW's Income from Continuing Operations at 3747464.0 in Q3 2025, 1753675.0 in Q2 2025, and 1971368.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.75 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -3.58 Mn |
| Sep 30, 2024 | 640,683.00 |
| Jun 30, 2024 | -1.98 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | -3.50 Mn |
| Sep 30, 2023 | -2.71 Mn |
| Jun 30, 2023 | -2.29 Mn |
| Mar 31, 2023 | -2.56 Mn |
| Dec 31, 2022 | -6.20 Mn |
| Sep 30, 2022 | -6.17 Mn |
| Jun 30, 2022 | -7.09 Mn |
| Mar 31, 2022 | -4.82 Mn |
| Dec 31, 2021 | -2.02 Mn |
| Sep 30, 2021 | -16.91 Mn |
| Jun 30, 2021 | -1.32 Mn |
| Mar 31, 2021 | -1.71 Mn |
| Dec 31, 2020 | -1.34 Mn |